11 Italian clinics now offers the K.O.S treatment for chronic rhinitis

Chordate's Italian distributor Ve.Di.Se. Hospital S.P.A. now has installations offering K.O.S treatment for chronic rhinitis in eleven clinics around the country, from Tradate and Verona in the north to Bari in the south. At the same time, Vedise's work with the introduction of K.O.S also as a treatment for chronic migraine in Italy continues.

“K.O.S is now starting to establish itself as a medical treatment in Italy and we expect that the number of clinics offering K.O.S for chronic rhinitis will continue to increase. The standstill of almost two years that Covid19 caused in Italy was longer than in most markets, the accumulated healthcare backlog is still tangible. Vedise's long experience and large network of clinics are also of great value in their ongoing work to introduce K.O.S as a treatment for chronic migraine”, says Chordate CEO Anders Weilandt.

Chordate and Vedise began their collaboration at the end of 2018 when the parties signed an exclusive distribution partnership for Italy. The K.O.S treatment is now offered for chronic rhinitis in eleven clinics, and the plan is to increase the number of clinics further in 2023. Since August 2022, Vedise is investing large resources in being able to start offering K.O.S also for chronic migraine.

“The positive results from the migraine study have given further momentum to this project. Italy is an important market for us, partly because it’s one of Europe's largest medtech markets and partly because we expect that K.O.S will soon be offered both for chronic rhinitis and chronic migraine in the country. That makes Italy a strong example of proof-of-concept for us”.

Vedise is a well-established player in the Italian market, having supplied medical devices to public hospitals and private clinics for over 30 years. The distributor has a close collaboration with the medical profession.

Read more about Vedise Hospital: https://vedise.com/

See where Vedise offers K.O.S for chronic rhinitis in Italy: https://vedisekos.it/ (the eleventh clinic, located in Rome, is not yet marked on the map).

Saudi Food and Drug Authority approves Janin Medical as Chordate Medical’s Authorized Representative in KSA

Chordate Medical announces that the Saudi Food and Drug Authority (SFDA) has approved the application for registration of Janin Medical Company ("Janin") as the company's Authorized Representative in KSA. This means, among other things, that Chordate now can fill waiting purchase orders from customers.

“The formal bureaucracy can be extensive in some markets and Saudi Arabia is no exception. We as exporters need to have an Authorized Representative registered with the competent authority in most markets. It is satisfactory that the application was approved relatively fast this time, a clear sign of effective collaboration between our General Manager for the GCC area and the new distributor. We have customer orders that have had to wait for this registration, and which are now possible to deliver near term, says Anders Weilandt, CEO of Chordate.

Chordate entered into the agreement with Janin, one of Saudi Arabia's leading medical device companies, in December 2022. The agreement means that Janin started as exclusive distributor in Saudi Arabia and Bahrain for both the migraine and rhinitis indications at new year. The company is a focused importer and distributor of advanced medical devices in neurology, pulmonary medicine, cardiology, speech therapy/audiology and urology. Janin also has the status to bid for public tenders.

More information about Janin Medical Company: https://janinmedical.com/index.html

The information was submitted, through the contact person below, for publication on February 24 at 10:00 2023 (CET).

Chordate Medical presents year-end report for 2022 in web conference on February 28th

Chordate Medical publishes its year-end report for 2022 on Tuesday, February 28, 2023, at 08:30 CET. On the same day, at 14:00 CET, CEO Anders Weilandt will present the report during a web conference. The conference is followed by a Q&A session. You can follow the conference via computer or mobile devices.

To register for the web conference, register via the following link: https://attendee.gotowebinar.com/register/3690216538735029342

The number of places is limited, so we recommend registering well in advance to secure a place.

A recording of the web conference will be available after the conference on the company's website www.chordate.com and on Västra Hamnen Corporate Finance's YouTube channel.

Chordate Medical’s joint venture submits application for product registration in China

Chordate Medical and Nanos Medical's joint venture Changyong Medical Technology Co. has submitted an application for product registration for the K.O.S treatment for chronic rhinitis in China.

“This is an important step towards market access in China. The next step in the project is entirely dependent on the answers we get from the Chinese supervisory authority's review work”, says Anders Weilandt, CEO of Chordate.

Chordate and Nanos Medical started a joint venture in 2018, forming the jointly owned company Changyong Medical Technology Co in Shanghai with the intention of marketing the K.O.S technology in the Chinese market. Nanos Medical owns two-thirds of this company and is the party that finances marketing and sales. Chordate owns the remaining third and will supply the Chinese patents when market authorization and product registration are in place.

Chordate Medical Holding ABs (publ) set-off share issue is now registered

Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") announces that the directed set-off issue to underwriters who have chosen to receive guarantee compensation in the form of newly issued shares in the Company announced on January 18, 2023 (the "Compensation Issue") has been registered with the Swedish Companies Registration Office (sw. “Bolagsverket”). Distribution of shares is expected to commence on January 25, 2023.

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Compensation Issue.

The information was submitted, through the contact person above, for publication on January 24 at 19.20 2023 (CET).

Chordate Medical Holding AB (publ) announces last day of trading in paid subscription shares (BTA)

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES.

The rights issue announced on November 17, 2022, with a last day for subscription on January 9, 2023 (the "Rights Issue") in Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") has been registered with the Swedish Companies Registration Office (sw. “Bolagsverket”) and paid subscription shares (“BTA”) will be converted to ordinary shares, Last day of trading in BTA is January 25, 2023 and the cut-off date with Euroclear Sweden AB is January 27, 2023, after which the distribution of shares to respective shareholder's VP account/custody account is estimated to take place from and including January 31, 2023 .

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Rights Issue.

The information was submitted, through the contact person above, for publication on January 20 at 17:05 2023 (CET).

Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade with shares, warrants or other securities in Chordate Medical. No measure has been taken and no measure will be taken to permit an offer to the public in any other jurisdiction other than Sweden. Any invitation to the persons concerned to subscribe for shares in Chordate Medical will only be made through the prospectus that Chordate Medical publishes today on Chordate Medical’s website, www.chordate.com. The Swedish Financial Supervisory Authority’s approval of the prospectus shall not be understood as an approval of Chordate Medical’s shares, warrants or other securities. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and this press release neither identifies nor purports to identify risks (direct or indirect) that may be connected with an investment in shares, warrants or other securities in Chordate Medical. Any investment decision should, in order for an investor to fully understand the risks and benefits associated with the decision to participate in the rights issue, be made solely based on the information in the prospectus. An investor is therefore advised to read the entire prospectus.

The information in this press release is not for release, publication or distribution, in whole or in part, directly or indirectly, within or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction where such actions would be unlawful, subject to legal restrictions or require other measures in addition to those required under Swedish law. Measures in violation of the restrictions may constitute a breach of relevant securities law.

No shares, warrants or other securities in Chordate Medical has been registered, and no shares, warrants or other securities will be registered under the United States Securities Act of 1933, as amended (the ”Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States.

Within the European Economic Area (the ”EEA”), no offer of shares, warrants or other securities (the ”Securities”) is made to the public in any other country other than Sweden. In other Member States of the European Union (the ”EU”), such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation (EU) 2017/1129. In other countries in the EEA that have implemented the Prospectus Regulation in national legislation, such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation and in accordance with any relevant implementation measures. In other countries in the EEA that have not implemented the Prospectus Regulation in national legislation, such an offer of securities can only be made in accordance with the applicable exemptions in national legislation.

In the United Kingdom, this press release, and other material in relation to the securities referred to herein, is only distributed to and directed at, and an investment or investment activity attributable to this press release is only available to, and will only be able to be exercised by ”qualified investors” (within the meaning of the UK version of Regulation 2017/1129 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in investments and fall within the definition of ”investment professional” in article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”), or (ii) ”high net worth entities” etcetera who fall within article 49(2)(a)-(d) of the Order; or (iii) such other persons whom such investment or investment activity may lawfully be directed to according to the Order (all such persons are collectively referred to as ”relevant persons”). An investment or investment activity to which this press release relates is available in the UK only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain certain forward-looking information that reflect Chordate Medical’s current view of future events as well as financial and operational development. Words such as ”intend”, ”assess”, ”expect”, ”may”, ”plan”, ”estimate” and other expressions involving indications or predictions regarding future development or trends, not based on historical facts, identify forward-looking statements. Forward-looking statements is inherently associated with both known and unknown risks and uncertainties as it is dependent on future events and circumstances. Forward-looking statements is not a guarantee of future performance or development, and the actual outcome may differ materially from what is stated in forward-looking statements.

Chordate Medical Holding AB (publ) carries out a directed set-off share issue to underwriters in the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES.

Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") intends to carry out a directed set-off share issue to underwriters who have chosen to receive underwriting fee in the form of newly issued shares in the Company (the "Compensation Issue") in accordance with the underwriting agreements which was entered into in connection with the rights issue announced on 17 November 2022 (the "Rights Issue"). The subscription price in the Compensation Issue is set at SEK 0.50 per share, which corresponds to the subscription price in the completed Rights Issue. Payment is made by way of set-off of the respective underwriters’ claim for underwriting compensation.

As previously communicated in connection with the Rights Issue, the underwriters had, in accordance with underwriting agreements entered into, the option to receive the underwriting fee in the form of cash compensation or in the form of newly issued shares in the Company. Due to the fact that a number of underwriters have informed the Company that they want to receive the underwriting compensation in the form of newly issued shares, the board, with the support of an authorization from the extraordinary general meeting held on 13 December 2022, has decided on the Compensation Issue, which amounts to a maximum of 1,320,000 shares.

The purpose of the Compensation Issue and the reason for the deviation from the shareholders' preferential rights is to fulfill the Company's obligations towards the underwriters as a result of the underwriting agreements entered into. In addition, Chordate Medical's board of directors believes that it is beneficial for the Company's financial position to take advantage of the opportunity to pay underwriters in the form of shares instead of cash. The Company has also recently carried out a Rights Issue which was not fully subscribed. Through the Compensation Issue, the Company can use a larger part of the proceeds from the Rights Issue in the manner described in the prospectus published on December 21, 2022 (the "Prospectus") in connection with the Rights Issue. Thus, the Compensation Issue is deemed to be beneficial for all shareholders.

Payment is made by way of set-off of the claim towards the Company, which consists of the respective underwriter’s compensation. The subscription price has been set at SEK 0.50 per share. The subscription price in the Compensation Issue corresponds to the subscription price in the completed Rights Issue. The subscription price in the Compensation Issue has been compared with the closing price on January 17, 2023, which was SEK 0.6795, entailing a discount of approximately 26 percent. The subscription price in the Compensation Issue has also been compared with the volume-weighted average price of the Company's share on the Nasdaq First North Growth Market during the period from and including January 3, 2023 to and including January 17, 2023, which was approximately SEK 0.625, entailing a discount of approximately 20 percent. Given the fact that the Rights Issue, with a subscription price of SEK 0.50, was not fully subscribed, and taking into account the weak market conditions on the stock market in general, the subscription price has been assessed as market price.

Through the Compensation Issue, the number of shares in Chordate Medical increases by 1,320,000 shares to a total of 232,416,507 shares, and the share capital increases by a total of SEK 330,000 to SEK 58,104,126.75 (calculated on the number of outstanding shares in the Company following the final registration of the Rights Issue and the Compensation Issue at the Swedish Companies Registration Office). The dilution effect due to the Compensation Issue amounts to approximately 0.6 percent (calculated on the number of outstanding shares in the Company following the final registration of the Rights Issue and the Compensation Issue at the Swedish Companies Registration Office).

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Rights Issue.

The information was submitted, through the contact person above, for publication on January 18 at 12.15 2023 (CET).

Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade with shares, warrants or other securities in Chordate Medical. No measure has been taken and no measure will be taken to permit an offer to the public in any other jurisdiction other than Sweden. Any invitation to the persons concerned to subscribe for shares in Chordate Medical will only be made through the prospectus that Chordate Medical publishes today on Chordate Medical’s website, www.chordate.com. The Swedish Financial Supervisory Authority’s approval of the prospectus shall not be understood as an approval of Chordate Medical’s shares, warrants or other securities. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and this press release neither identifies nor purports to identify risks (direct or indirect) that may be connected with an investment in shares, warrants or other securities in Chordate Medical. Any investment decision should, in order for an investor to fully understand the risks and benefits associated with the decision to participate in the rights issue, be made solely based on the information in the prospectus. An investor is therefore advised to read the entire prospectus.

The information in this press release is not for release, publication or distribution, in whole or in part, directly or indirectly, within or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction where such actions would be unlawful, subject to legal restrictions or require other measures in addition to those required under Swedish law. Measures in violation of the restrictions may constitute a breach of relevant securities law.

No shares, warrants or other securities in Chordate Medical has been registered, and no shares, warrants or other securities will be registered under the United States Securities Act of 1933, as amended (the ”Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States.

Within the European Economic Area (the ”EEA”), no offer of shares, warrants or other securities (the ”Securities”) is made to the public in any other country other than Sweden. In other Member States of the European Union (the ”EU”), such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation (EU) 2017/1129. In other countries in the EEA that have implemented the Prospectus Regulation in national legislation, such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation and in accordance with any relevant implementation measures. In other countries in the EEA that have not implemented the Prospectus Regulation in national legislation, such an offer of securities can only be made in accordance with the applicable exemptions in national legislation.

In the United Kingdom, this press release, and other material in relation to the securities referred to herein, is only distributed to and directed at, and an investment or investment activity attributable to this press release is only available to, and will only be able to be exercised by ”qualified investors” (within the meaning of the UK version of Regulation 2017/1129 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in investments and fall within the definition of ”investment professional” in article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”), or (ii) ”high net worth entities” etcetera who fall within article 49(2)(a)-(d) of the Order; or (iii) such other persons whom such investment or investment activity may lawfully be directed to according to the Order (all such persons are collectively referred to as ”relevant persons”). An investment or investment activity to which this press release relates is available in the UK only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain certain forward-looking information that reflect Chordate Medical’s current view of future events as well as financial and operational development. Words such as ”intend”, ”assess”, ”expect”, ”may”, ”plan”, ”estimate” and other expressions involving indications or predictions regarding future development or trends, not based on historical facts, identify forward-looking statements. Forward-looking statements is inherently associated with both known and unknown risks and uncertainties as it is dependent on future events and circumstances. Forward-looking statements is not a guarantee of future performance or development, and the actual outcome may differ materially from what is stated in forward-looking statements.

Chordate Medical Holding AB’s (publ) rights issue was subscribed to approximately 72 percent

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES.

The board of Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") today presents the outcome of the rights issue, announced on November 17, 2022, with a last day for subscription on January 9, 2023 (the “Rights Issue"). A total of 64 066 041 shares, corresponding to approximately 62.5 percent of the Rights Issue, were subscribed with the support of subscription rights. In addition, 9 318 086 shares were subscribed without the support of subscription rights, corresponding to approximately 9.1 percent of the Rights Issue, of which approximately 6.3 percent refers to subscription attributable to the underwriting arrangement provided. A total of 73 384 127 shares were subscribed, thus the Rights Issue was subscribed to approximately 72 percent.

Through the Rights Issue, Chordate Medical will receive approximately 36.7 million SEK before issue costs, expected to amount to approximately 3.8 MSEK. Through the Rights Issue, the number of shares in Chordate Medical increases by 73 384 127 shares from 157 712 380 shares to 231 096 507 shares and the share capital increases by 18 346 031.75 SEK from SEK 39 428 095 to 57 774 126.75 SEK.

Trading in paid subscribed shares (“BTA”) on the Nasdaq First North Growth Market continues under the short name CMH BTA until the Rights Issue has been registered with the Swedish Companies Registration Office (sw “Bolagsverket”), which is expected to take place towards the end of January 2023. After that, the BTA will be converted into shares.

Allotment of shares subscribed without the support of subscription rights has taken place in accordance with the principles stated in the prospectus compiled in connection with the Rights Issue and which was published by the Company on December 21, 2022. Notification of allotment is made through a settlement note that is sent by mail to each subscriber. Allotted shares must be paid in accordance with the instructions on the settlement note.

CEO Anders Weilandt comments:

“We are very satisfied with the outcome of the rights issue and would like to thank all our shareholders for their confidence in Chordate. We see the fact that so many have chosen to continue investing in the Company's journey towards an exit as an unusually good rating of the strength of Chordate's offer, especially under the current stock market conditions. Now we can increase the speed in the work to reach out to more people in our prioritized markets.”

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Rights Issue.

Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade with shares, warrants or other securities in Chordate Medical. No measure has been taken and no measure will be taken to permit an offer to the public in any other jurisdiction other than Sweden. Any invitation to the persons concerned to subscribe for shares in Chordate Medical will only be made through the prospectus that Chordate Medical publishes today on Chordate Medical’s website, www.chordate.com. The Swedish Financial Supervisory Authority’s approval of the prospectus shall not be understood as an approval of Chordate Medical’s shares, warrants or other securities. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and this press release neither identifies nor purports to identify risks (direct or indirect) that may be connected with an investment in shares, warrants or other securities in Chordate Medical. Any investment decision should, in order for an investor to fully understand the risks and benefits associated with the decision to participate in the rights issue, be made solely based on the information in the prospectus. An investor is therefore advised to read the entire prospectus.

The information in this press release is not for release, publication or distribution, in whole or in part, directly or indirectly, within or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction where such actions would be unlawful, subject to legal restrictions or require other measures in addition to those required under Swedish law. Measures in violation of the restrictions may constitute a breach of relevant securities law.

No shares, warrants or other securities in Chordate Medical has been registered, and no shares, warrants or other securities will be registered under the United States Securities Act of 1933, as amended (the ”Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States.

Within the European Economic Area (the ”EEA”), no offer of shares, warrants or other securities (the ”Securities”) is made to the public in any other country other than Sweden. In other Member States of the European Union (the ”EU”), such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation (EU) 2017/1129. In other countries in the EEA that have implemented the Prospectus Regulation in national legislation, such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation and in accordance with any relevant implementation measures. In other countries in the EEA that have not implemented the Prospectus Regulation in national legislation, such an offer of securities can only be made in accordance with the applicable exemptions in national legislation.

In the United Kingdom, this press release, and other material in relation to the securities referred to herein, is only distributed to and directed at, and an investment or investment activity attributable to this press release is only available to, and will only be able to be exercised by ”qualified investors” (within the meaning of the UK version of Regulation 2017/1129 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in investments and fall within the definition of ”investment professional” in article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”), or (ii) ”high net worth entities” etcetera who fall within article 49(2)(a)-(d) of the Order; or (iii) such other persons whom such investment or investment activity may lawfully be directed to according to the Order (all such persons are collectively referred to as ”relevant persons”). An investment or investment activity to which this press release relates is available in the UK only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain certain forward-looking information that reflect Chordate Medical’s current view of future events as well as financial and operational development. Words such as ”intend”, ”assess”, ”expect”, ”may”, ”plan”, ”estimate” and other expressions involving indications or predictions regarding future development or trends, not based on historical facts, identify forward-looking statements. Forward-looking statements is inherently associated with both known and unknown risks and uncertainties as it is dependent on future events and circumstances. Forward-looking statements is not a guarantee of future performance or development, and the actual outcome may differ materially from what is stated in forward-looking statements.

Chordate granted new patent by the European Patent Office

Chordate Medical Holding AB (publ) ("Chordate", the "Company") announces that the European Patent Office intends to grant Chordate's patent application EP 17168265.1 from 2017. The patent application relates to further development of the Company's treatment technology for primarily chronic migraine, Kinetic Oscillation Stimulation, K.O.S.

“The aim of further expanding the patent portfolio is to make it more difficult for a potential competitor to enter our market. The company's intellectual property enables exclusivity in the market, which is a cornerstone of the shareholder value the company is building", says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical holds approximately 71 patents across 26 countries and 9 patent families, covering various aspects of the company's treatment technologies. The granting of application EP 17168265.1 adds further patents to a growing portfolio that the company started to build in 2008.

Subscription period in Chordate Medical Holding ABs (publ) rights issue ends on 9th January

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES.

As previously announced, Monday, January 9th, 2023 is the last day for subscription in Chordate Medical Holding AB's (publ) ("Chordate Medical" or the "Company") rights issue of approximately SEK 51.3 million (the "Rights Issue"). The last day for subscription without exercise of subscription rights via Avanza and Nordnet is Sunday, January 8th, 2023. For VP-account subscription without exercise of subscription rights, please use download and fill in form on Chordate Medical's website https://www.chordate.com/en/rights-issue-2022. The completed form must be sent to Aqurat Fondkommission, info@aqurat.se, no later than 3 p.m. Monday 9th, January 2023.

Full terms and conditions and instructions for the Rights Issue, as well as other information about the Company is presented in the prospectus compiled in connection with the Rights Issue and that is available on Chordate Medicals website as above.

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Rights Issue.

Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade with shares, warrants or other securities in Chordate Medical. No measure has been taken and no measure will be taken to permit an offer to the public in any other jurisdiction other than Sweden. Any invitation to the persons concerned to subscribe for shares in Chordate Medical will only be made through the prospectus that Chordate Medical published on December 21st 2022 on Chordate Medical’s website, www.chordate.com. The Swedish Financial Supervisory Authority’s approval of the prospectus shall not be understood as an approval of Chordate Medical’s shares, warrants or other securities. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and this press release neither identifies nor purports to identify risks (direct or indirect) that may be connected with an investment in shares, warrants or other securities in Chordate Medical. Any investment decision should, in order for an investor to fully understand the risks and benefits associated with the decision to participate in the rights issue, be made solely based on the information in the prospectus. An investor is therefore advised to read the entire prospectus.

The information in this press release is not for release, publication or distribution, in whole or in part, directly or indirectly, within or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction where such actions would be unlawful, subject to legal restrictions or require other measures in addition to those required under Swedish law. Measures in violation of the restrictions may constitute a breach of relevant securities law.

No shares, warrants or other securities in Chordate Medical has been registered, and no shares, warrants or other securities will be registered under the United States Securities Act of 1933, as amended (the ”Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States.

Within the European Economic Area (the ”EEA”), no offer of shares, warrants or other securities (the ”Securities”) is made to the public in any other country other than Sweden. In other Member States of the European Union (the ”EU”), such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation (EU) 2017/1129. In other countries in the EEA that have implemented the Prospectus Regulation in national legislation, such an offer of Securities can only be made in accordance with the exemptions in the Prospectus Regulation and in accordance with any relevant implementation measures. In other countries in the EEA that have not implemented the Prospectus Regulation in national legislation, such an offer of securities can only be made in accordance with the applicable exemptions in national legislation.

In the United Kingdom, this press release, and other material in relation to the securities referred to herein, is only distributed to and directed at, and an investment or investment activity attributable to this press release is only available to, and will only be able to be exercised by ”qualified investors” (within the meaning of the UK version of Regulation 2017/1129 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in investments and fall within the definition of ”investment professional” in article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”), or (ii) ”high net worth entities” etcetera who fall within article 49(2)(a)-(d) of the Order; or (iii) such other persons whom such investment or investment activity may lawfully be directed to according to the Order (all such persons are collectively referred to as ”relevant persons”). An investment or investment activity to which this press release relates is available in the UK only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain certain forward-looking information that reflect Chordate Medical’s current view of future events as well as financial and operational development. Words such as ”intend”, ”assess”, ”expect”, ”may”, ”plan”, ”estimate” and other expressions involving indications or predictions regarding future development or trends, not based on historical facts, identify forward-looking statements. Forward-looking statements is inherently associated with both known and unknown risks and uncertainties as it is dependent on future events and circumstances. Forward-looking statements is not a guarantee of future performance or development, and the actual outcome may differ materially from what is stated in forward-looking statements.